Grifols develops and produces plasma-derived medicines and biopharmaceutical solutions, transfusion medicine and diagnostic technologies, serving more than 110 countries with over 23,000 employees.
Grifols is a global healthcare company that develops, produces and supplies plasma-derived medicines and other biopharmaceutical solutions for patients with chronic, rare and life-threatening conditions. Founded in Barcelona in 1909, the company is a pioneer in the plasma industry and operates the largest network of plasma donation centres worldwide. Its technical work spans plasma fractionation, biopharmaceutical production and pharmaceutical manufacturing.
Beyond plasma-derived medicines, Grifols maintains a portfolio in transfusion medicine designed to improve safety from donation to transfusion, alongside clinical diagnostic technologies. It also supplies biological materials for life-science research and pharmaceutical manufacturing. The therapeutic areas served include immunology, infectious diseases, pulmonology, critical care, hepatology, haematology and neurology.
The company employs more than 23,000 people across over 30 countries and regions, and serves customers in more than 110 countries, with operations in North America, Europe, Africa, the Middle East and China. Its stated focus is on improving the health and well-being of people worldwide, with an emphasis on patient-centric care in rare and serious disease.
